reason report
bottom line ahead upcom earli januari investor
conferences/meet earn offer believ
relev question manag team across
med-tech coverag univers follow page includ five
key question and/ topic compani coverag univers
well pre-announc primer also provid
insight around stock incom call volum
highest controversi head typic busi
pre-announce season coincid competitor confer
op expect compani pre-announce solid broad-
base beat like gener season
stronger quarter cardio help seem faster
roll-out japan also expect compani rais guidanc
sale growth sale growth larg reflect
out-performance import number updat
manag may provid stemi like clinic trial design time
potenti approv think stemi might
contribut
op expect in-lin better revenue pre-announce
consensu revenue growth management reiter least
revenue growth outlook origin provid believ
help increas investor confid compani still plenti
growth opportun front distributor execut issu
fact rear view growth outlook
op expect compani pre-announce yet anoth
strong beat like come well y/i
potenti reach believ street model
current reflect greater sensor price eros model anoth
point declin sequenti like transpir increment
upsid also possibl new patient add also provid
guidanc expect come rang
midpoint ahead consensu like commentari
around current instal base provid investor increment
color market share pace new patient add wed expect
manag provid updat though like meaning differ
heard decemb analyst day price
dynam pipelin verili
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
op expect in-lin better revenue pre-announce
conjunct co earli jan annual sale meet think
rev/ep includ upsid like come us core spine
growth model think could better robot placement
least growth ebitda margin
bigger focu guidanc think management revenue outlook
bracket consensu ep guidanc could come
penni street rang vs consensu
think fear even wors might met
sigh relief link
op dont expect pre-announce
compani alreadi issu guidanc
y/i highlight stock one that rel controversi
weve gotten high volum incom question larg part
driven dramat sell-off share high sinc
mid-septemb could prompt manag pre-announce
particularli sinc think like compani deliv anoth
above-consensu quarter without pre-announce expect
manag provid updat sale rep exit
compani exit rep nearli y/i wed
expect least anoth rep ad
reiter compani state oxygen therapi
patient poc address
grow net rate per year
op unclear whether pre-announce
could get updat soon jan regard evid street
es technolog assess cross shield bcb
assess could help facilit posit coverag polici
next month across bcb region network upgrad
level moder level would best realist outcom
expect would mean might stand benefit
reimburs tailwind aetna bcb time
vs our/curr consensu forecast factor littl
contribut addt insur coverag decis beyond aetna
es maintain uncertain rate increas
none notch would disappoint believ
would put consensu estimateor upsid potenti matterat
risk given bcb statu quo alreadi uncertain
realli get wors view stock see pressur less-
than-hop upward rate move would recommend buy
opportun importantli see signific estim upsid potential/
momentum aetna effect alonewithout increment
contribut bcb coverag decisionsand aetna impact
get even stronger
op expect rev/ep pre-announce beat driven ww
system placement procedur upsid expect
initi procedur outlook like bracket consensu project
lpe toward mid-point upper-end rang
repres conserv base case start year
management tend take conserv approach guidanc onset
year upper end rang highli achiev beatabl
track exceed upper end origin issu
procedur guidanc rang least
compani exceed upper end initi guidanc rang
 respect expect similar approach guidanc
year high confid head around still
under-penetrated us gen surgeri area potenti acceler
momentum japan plu china capac expans horizon
mp expect in-lin better revenue pre-announce less
confid ep beat think management may hold issu
offici ep outlook given new ceo chri barri took rein
start nov may see need step-up invest potenti
result lower consensu earn outlook suspect
would like save discuss offici earn call would
surpris management back hard commit relat
long-held least annual margin improv believ
consensu ep expect still need re-set lower link
offici robot arm launch puls navig platform could
op expect in-lin better revenue pre-announce
revenue outlook believ management like issu growth guidanc
rang bracket consensu see upsid
could end impli growth rang approxim albeit slightli
midpoint understand
compani placehold revenue growth guidanc
alway contempl vs management guidanc assumpt
thu management might take opportun upsid scenario guid
slightli ensur consensu estim dont creep fast
start year conserv bent
becton dickinson compani
wednesday januari
note compani highlight green compani believ pre-announce compani consist pre-announce preliminari result and/or
provid annual outlook year ahead week
china exposur nr note significantli greater macro weak
emerg market specif china key factor consid china
exposur macro weak true impact growth trajectori near-term
long-term impact consumer-fac product nutrit vs
hospit product plan manag
nutrit diagnost establish pharmaceut look portfolio
holist stj aler hand seemingli significantli strengthen
competit posit within hospit given broader portfolio plan
leverag strength area need build scale order ultim
compet environ see increas rate multilin contract
capit deploy compani complet integr stj alr abt
prioriti capit deploy perspect compani seemingli track reduc
gross debt exit balanc debt pay dividend
 remain prioriti strategi busi
gape hole focu technolog geograph distribut
margin expans stj aler acquisit complet see
acceler margin expans increment driver posit oper
leverag long-term ultim manag see peak margin
potenti busi stand today
sustain organ growth compani track deliv organ growth
sustain given tougher comp libr drive robust
adopt sustain adopt momentum beyond
recently-approv freestyl libr product like attract type
patient fda approv gener mitraclip posit data present tct
transcathet cardiovascular therapi septemb think growth
opportun mitral repair/replac market diagnost expect see continu
growth acceler alin neuromodul quickli manag
hire issu revenu base annual impact new
product launch expect first month
stemi think trial design limit stemi market opportun
trial need show order secur approv drive adopt
long-term growth outlook well track achiev long-term sale vision
street alreadi estim sale long-term
sale vision includ meaning pipelin contribut
increment driver potenti upsid long-term guidanc street estim beyond
next long-term sale aspir manag see sustain
growth trajectori anoth indic come on-line
japan launch see adopt ramp limit launch mani hospit
current approv expect broader roll-out ultim feel like
your track rel balloon pump ecmo done per year
penetr perspect line expect drive better-
than-expect adopt far barrier adopt japan
increment margin expans compani approach long-term oper margin
goal could ultim oper margin beyond
gross margin could expect oper margin exceed ultim long-
term downsid risk margin gross oper whether relat manufactur
pipelin come pipelin could drive increment adopt and/or
expand indic benefit ecp chang assumpt
potenti peak penetr next pipelin beyond stemi new product
like ecp chang assumpt growth outlook potenti peak penetr
long-term area could leverag compet temporari
hemodynam support drive increment adopt and/or expand whether new
indic new technolog
price promot compani implement na price promot pilot
contribut asp declin in-qtr investor brace spill-ov impact
price promot typic prior qtr volum compani
plan activ manag type pilot promot avoid downward
pressur think
teen segment could potenti year teen segment see inflect point
increas invisalign adopt market addtl dtc marketing/sal
initi compani plan launch help drive increas demand invisalign
among teen reason growth acceler level
mandibular advanc fda approv launch
much class ii malocclus expand algn exist annual procedur
think revenue cadenc potenti acceler teen growth
product receiv physician marketplac initi phase
competit management anticip invisalign case volum price
impact new entrant dentspli henri schien algn
potenti respons anticip new entrant especi lower volum account
could potenti price pressur
margin reason assum could year see op margin expans
despit continu invest busi key invest prioriti compani
would take compani deliv low-end lt op
margin target
converg updat timelin converg manag expect
data present given converg superior trial
bogey recurr rate convers efficaci clinician order drive adopt
anticip pma approv go-to-market strategi converg
procedur compet standard cathet ablat train session look like
long-term growth trajectori sustain growth profil
busi open ablat mi atriclip biggest risk achiev
open ablat improv guidelin impact adoption/volum tavr move
risk curv sustain market growth outlook surgic ablat
driver quickli physician ramp volum attend advanc train
session effort compani undertak drive physician awar besid
deep latest updat deep-af converg complet enrol
role deep procedur mi
profit pathway achiev sustain profit manag expect
deliv posit ebitda
trauma market oppti sourc key assumpt give management confid
pni trauma pni incid rate compani assum mani elig
breast reconstruct neurot brn compani plan expand reach new
center maintain narrow commun center investor expect
see preliminari data sensation-now compani plan enrol singl vs
dual neurot trial sense-ii compani work secur reimburs
resens technique/procedur advis doc get reimburs
surgic manag pain think launch time
revenue contribut could begin materi plan begin enrol
clinic studi repos rct-rescet neuroma pain registri reason
time-frame expect see preliminari data product use deriv initi
competit mgmt view nexgen conduit product bax/synovi
talk management anticip could potenti impact busi
-- axoguard nerveconnector avanc compani awar compani
revenu growth management issu revenue guidanc least growth despit
recent qtrli trend management expect base compani
outperform underli reason growth could deceler
factor growth driver give management confid growth profil sustain beyond
medic deliveri turnaround manag seen notabl chang practic due
suppli issu could indic fundament long-term chang market dynam
effort compani undertak recov trajectori recoveri look
like factor consid medic deliveri busi near-term
 strategi gap product portfolio compani eager fill
excit new market compani develop realiz
leverag much will lever make acquisit upward
bound potenti deal size criteria place potenti acquisit
accret strateg fit perspect current valuat devic compani
get attract see chang strategi near medium term
capit deploy bax updat thought capit deploy prioriti
much will lever quickli aggress deploy capit rel
last year capit deploy strategy/prior chang
grown faster expect
sale growth trajectori give manag confid long-rang plan
sale compound-annual-growth-rate time-frame remain intact tailwind
acceler growth beyond key driver potenti off-set
protract weak medic deliveri nutrit think
bax underli oper sale growth rate
increment margin expans drive better-than-expect oper margin
expans sinc spin cost-cut product mix low-hang fruit
seemingli pick margin expans side drive increment margin improv
ultim manag see peak margin potenti busi
stand today
expect management continu expect low point revenue
ep consensu model cadenc correctli differ compon
impact rev/ep fx flu season etc reason assum rev/ep see
increas sequenti
organ revenu growth growth driver place across differ busi
give management confid org cc revenue growth achiev meant
base management hope outperform given came high-end rang
growth driver place em give management confid growth
em low dd growth china
bcr revenu synergi cadenc anticip revenue synergi look like
revenue synergi initi alreadi complet time
complet look like initi in-process cost synergi initi alreadi
complet compani focus sourc
potenti upsid deliv cost benefit beyond management commit
swatch patch market management expect swatch approv
submit think cadenc revenue contribut
beyond current competit landscap patch pump swatch price
pariti insulin pen-bas therapi investor expect see data
lutonix below-the-kne btk indic management still estim market oppti
management expect btk approv pma submit think
cadenc revenue contribut beyond
sustain organ sale growth trajectori sustain organ sale growth rate
manag envis near long-term near-term
uncertainti around time major pipelin product top-lin growth
acceler year tailwind headwind consid look
next month long-term manag believ above-market sale growth
sustain mix busi
integr btg anticip complet btg acquisit
manag recent thought integr potenti sale cost synergi
oper margin goal increment driver sale growth margin expans
longer term within peripher busi whole plan lower-growth
capit deploy liabil overhang larg remov exit
bsx capit deploy strategi beyond btg acquisit manag priorit
debt pay dividend share buyback point consid pay
pipelin anticip lotu edg europ re-launch launch
manag strategi regain lost market share tavr long manag
estim take rebuild credibl lotu edg re-launch europ scope data
releas expect go-to-market strategi chang two
transcathet valv launch market acquisit milliped what
manag view competit landscap number differ valv
develop role valv replac vs repair market split
two eluvia drive out-performance share gain posit
margin expans sever year meaning improv inning
driver increment margin expans
growth outlook broad deep pipelin build around revascular
chang manag mind transit pipelin stori singl product
compani underli growth rate manag forecast core atherectomi
busi broader product pipelin build around atherectomi manag
strategi strengthen posit competit complet toolkit revascular
achiev long-term guidanc csii goal achiev revenu
repres sale compound-annual-growth-rate reflect sale geograph
expans new product launch give manag confid
success bring product market achiev ambiti long-term plan
what view ultim sale rep product point manag expect
core atherectomi busi full scale rep product perspect
guidanc despit comp get tougher throughout key driver
growth acceler tailwind headwind consid
guidanc assum oem product intern
expect becom meaning contributor
long-term growth trajectori manag believ long-term sale growth
trajectori csii busi peripher coronari
driver impact on-going clinic trial liberti eclips
atherectomi growth broadli specif long-term think
growth opportun atherectomi knee btk impact drug-coat
balloon pull-through knee sort impact less would expect
pathway profit pathway profit key lever drive
on-going margin expans think timelin sustain net incom
 orthoped busi growth driver place give management confid us
ortho busi continu multi-qtr trend acceler growth take
grow broader us ortho market growth rate mani new product
compani plan launch
gross margin op leverag much increment invest requir continu
acceler revenue management expect anoth year invest minim
leverag leverag long-term goal post investor
think regard op margin could go next year
airseal proport gen surg sale come airseal reason assum
airseal platform continu increas sale low dd growth rate in-lin robot
market pull revenue opportun cross sell materi legaci
gener surgeri portfolio addtl initi platform help enabl
buffalo filter bf llc bf deal expect close revenue cadenc
look like given mgmt revenue expect compon make
compani ebitda synergi yr management bucket potenti revenue cost
synergi long could take materi compani plan bring
manufactur in-hous could mean potenti accret cnmd
gm average cost capit equip recur revenu compon
 mgmt strategi reason think cnmd ortho divis
could see addit tuck-in given recent bf acquisit gen surg divis
long-term guidanc dxcm long-term revenu target impli
sale compound-annual-growth-rate time-frame headwind tailwind
cogniz next year potenti sourc posit upsid
surpris downsid risk
competit landscap manag view market dynam role
manag think abt gener freestyl libr senss
eversens play market think impact new patient
adds/attrit commerci medicar
outlook put take guidanc could drive faster slower
sale growth manag expect tailwind headwind adopt
market access price pressur could impact sale growth beyond
pharmaci price cover live cover pharmaci
channel instal base shift pharmaci channel
transit look like think price drive acceler adopt
pharmaci channel price flexibl also maintain current
type icgm design timelin gen verili product
could time product move see data releas
verili product mard time rang etc expect price point product
intermedi risk just-issu sale guidanc
tavr sale growth put take guidanc much sale
contribut expect low risk indic manag expect gain market
share sapien ultra launch
risk regard anticip data march
bogey safeti efficaci durabl data long-term clinic data clinician order
drive adopt could low risk adopt follow similar trajectori intermedi risk
reason could faster slower hurdl low risk adopt
drive differ ramp trajectori saw intermedi risk adopt
competit landscap market share split ew today
us europ intermedi risk approv delay lotu edg
happen market player enter particularli price perspect
manag see meaning long-term risk price portico launch assum
play market share
litig next step germani manag quantifi
potenti impact case
mitral mitral advanc clinic much expect increment spend
key clinic mileston look next month
tmtt transcathet mitral tricuspid therapi sale factor guidanc
realist time frame within mitral begin contribut revenu
revenu growth management indic floor revenue analyst day oct
management view potenti upsid driver potenti risk revenu
beyond reason think elgx could hsd grower beyond given
multipl new product cycl tap
sale forc stabil management believ compani remain track above-
normal sale forc attrit rate behind compani enter chang management
observ sale forc moral sinc implement tiered/performance-bas structur
factor increas mgmt confid sale forc stabil beyond
balanc sheet debt/liquid concern still top investor mind option
compani evalu term refinanc convert management anticip
refin convert management anticip reduc cash burn
factor give management confid compani abl achiev level cash
burn break-even
ovat alto management expect ovat alto approv mgmt view
potenti likelihood fda requir panel investor think
cadenc revenue growth much alto revenue contribut contempl mgmt
nellix nellix clinic trial expect nellix intenational growth rate stabil gain
posit momentum refin ifu nexgen platform necessari
stimul growth compani remain track complet enrol
nellix eva trial respect nellix cheva
compani plan submit trial design long typic take fda
approv compani target begin enrol still reason assumpt
 spine market spine market appear stabl improv rang
give management confid stabil us spine end-mkt rate growth rate
management forecast underli spine market contempl guidanc
factor give management confid sustain above-market growth rate ex emerg
robot -- competit start run mdt/mazor launch nexgen
robot w/ stealth tech mdt strategi place system exchang volum
commit impact gmed abil place system give management confid
stay ahead competit might unveil new robot indic area
like target next
trauma remain track soft launch even though manufactur
initi taken longer origin anticip get run
think revenue cadenc throughout gradual sequenti growth
compani plan evolv trauma technolog becom domin player space
time
 spine robot implant pull-through extent robot implant pull-through
impact us core spine growth accel implant pull-through
drive growth accel categori reason assum robot implant pull-through
could add compani underli us core spine growth top new msd run
busi factor give management confid intern growth accel
beyond compani stand intenational initi drive growth
upgrad leadership increas educ reason assum intenational busi
return low-to-mid teen growth rate
margin sustain margin expans potenti reason
compani wouldnt begin see ebitda margin expans trauma revenu begin
materi bigger way even commit reinvest reason assum
y/i margin expans potenti
breast health bh growth bh continu primari driver sale upsid recent qtr
mgmt msd revenue growth guidanc impli deceler level msd growth
expect base case management hope outperform similar play
give management confid sustain dd growth intenational bh busi
underli busi trend would signal slowdown imag intervent
product growth mani increment account faxitron focal
acquisit open
diagnost factor contempl mgmt guidanc get low-end lsd
high-end msd revenue growth reason assum primari growth driver
continu drive fuel growth molecular women health virolog assay
regard cytolog perinat segment reason assum prevent
servic task forc uspstf grade co-test pap hpv help propel
busi growth challeng
gyn surgic busi recent launch omni hysteroscop compat
myosur offer much revenue contribut mgmt low- mid- singl digit
growth guidanc contempl could product provid oppti pull-through addtl
myosur case accel growth factor give management confid
us gyn growth momentum cont
tempsur tempsur surgic rf platform launch dec
competit rf platform offer seamless integr surgic non-surg aesthet
capabl compani also reintroduc vitalia hand piec chang
make product label/promot materi address fda concern could
reintroduct help accel medic aesthet growth high-end msd
guidanc rang given
monalisa touch mlt chang make mlt claim market materi
compli fda concern given still uncertainti marketplac energy-
base women health product step compani take educ physician
restor confid mlt product impact compani expect
significantli less mlt sale
total address market manag get
estim patient popul think patient new
oxygen therapi enter market per year vs patient pass away
look current poc penetr base assess
plan leverag dtc infrastructur poc approach peak penetr like next
year market like move back rental model patient unlik purchas
poc outright secur poc free dme manag
plan leverag dtc infrastructur manag activ list potenti
acquisit manag approach possibl markets/technolog best
fit busi model
outlook given sale guidanc impli growth
guidanc midpoint bullish guidanc manag given to-
date start year put take guidanc could drive faster
slower sale growth manag biggest potenti sourc posit upsid
surpris convers biggest potenti risk signific sourc
upsid last sever quarter still increment runway upsid sale
might impact competit launch market share price
busi seemingli major driver long-term growth
manag think adopt curv given domest saw signific
deceler -- vs nearli growth -- seen
notabl chang adopt pattern whether independ mom-and-pop shop
larg nation player within specif geographi driver lumpi
busi
posit oper leverag manag view reason long-term oper
margin goal busi steadili ad new sale rep drive growth
compani gener increment posit leverag on-going basi
key area invest opex perspect ramp invest sell
market put pressur near-term oper margin
sinuva j-code factor give management confid abil secur perman j-code
sinuva effect asid categori code sunset factor
compani differ recent applic
sinuva reimburs sever insur compani adopt posit coverag decis
aetna ad sinuva formulari optumrx
management anticip impact buy-and-bil bnb and/or specialti pharmaci commerci
channel fair assum formulari decreas relianc bnb help acceler
specialti pharmaci channel approv get faster
dcb pipelin product consider respect regulatori approv
clinic evalu product would result clearanc toward earlier part
manag initi estim commerci time-frame year right
time pursu new product initi area manag believ taken
long someon pursu dcb given balloon sinuplasti approv
gain use
guidanc y/i revenue growth investor think
compon growth base biz sinuva consensu low-teen
base biz growth sinuva forecast reason anoth way
street think sale mix
gross margin management anticip gm ineffici contour sinuva
product ramp carri management anticip return
bcbs/evid street review long would take re-submit evalu
evid street es current one result unchang rate upward
revis guarante bcb plan establish posit coverag long could take
region bcb plan write polici investor make chang current
rate anoth review delay
addit reimburs insp reimburs team secur addtl
reimburs decis larg insur management contempl model
addit coverag decis time-frame reason assum least
major insur like aetna pick coverag within next month
aetna effect aetna alreadi begin posit impact end give
management confid continu posit impact prior author submiss
approv proport approv management contempl
guidanc aet submissions/resubmiss
physician econom inspir procedur particularli compel physician
econom compar surgeri per unit time basi point management think
econom could potenti effect pace/veloc adopt much runway among
earli adopt academia physician econom could becom gate
factor compani stand secur code recent deni
capit alloc recent complet capit rais secondari equiti offer
compani alloc fund mgmt key invest
procedur growth drivers/consider reason assum procedur
growth driver look similar drove increas adopt key new gen
surgeri area like hernia penetr sustain above-trend growth us urolog
gynecolog given multipl tailwind horizon associ japan reimburs
eventu china capac expans reason growth would
deceler vs level least abl sustain growth y/i
quickli management think avail stapler drive inflecting/acceler
adopt bariatr part gen surgeri
china bottleneck consid time tender process updat
quota system china announc fall play come
months/year system sold long average take train surgeon
hospit get run reason assum quota expans could theoret
repres much addtl procedures/yr full capac time assum
higher average rate util vs us system
sp ion flexibl cathet factor contribut gate sp roll-out
us investor expect sp full-scal us launch mkt
expect learn time new indications/addtl procedur target
key
advantages/disadvantag ion vs auri surgic monarch system alreadi us
market type addit diagnosis/therapi applic might platform like ion
well-suit futur beyond lung biopsi
reinvest futur growth/op leverag management anticip anoth
invest year no/minim leverag key area management
focu spend next month sale support train
come
competit management pick increas awareness/interest/chatt among exist
prospect custom respect new robot platform and/or
year specif
features/attribut management expect platform tri compet extent
isrg instal base risk get poach -- -i competit system come
-- -given rise proport system get place flexibl financ arrang
like oper leas and/or usage-bas arrang lower switch cost
market point
next
capit deploy jnj strong cash gener capabl alreadi signific cash
hand jnj capit deploy prioriti chang
 strategi highest prioriti perspect across within
busi manag see gape hole product offer
pipelin ultim need fill strategi within busi whether
in-licens vs outright acquisit acquisit technolog vs geograph distribut etc
criteria perspect deal size accretion/dilut etc
current valuat devic compani get attract see chang
strategi near medium term
long-term medic devic strategi long-term growth rate medic devic
busi current state busi whole return in-lin market growth
rate without shed under-perform busi procedur volum
grow price perpetu pressur scale
perspect multilin contract long under-sc cardiolog
compani lose competit foot decid build scale cardiolog
sub-market import within exist portfolio import
product launch next month robot
pharma growth outlook recent zytiga litig appropri growth
outlook sustain recent growth rate compani subject
below-market growth work zytgia gener headwind help us understand
put take pharma growth outlook next month key
risk downsid upsid growth pharma busi off-set
zytiga declin sustain recent profit level expect pressur
consum market growth rate consum busi
stage inning consum turnaround implement growth driver within
consum lever pull continu drive margin expans ramp
invest turn busi around
sale growth trajectori manag guidanc impli growth deceler
increment driver beyond tougher comp think sale
growth trajectori manag lower long-term organ sale growth
realist return mid-single-digit sale growth quickli sustain
given end-us market competit product cycl tailwind
acceler growth headwind consid could hinder
mdt abil return mid-single-digit sale growth
pipelin pipelin product critic mdt abil reacceler
sale growth restor compani mid-single-digit growth near medium
term think contribut growth key new product launch
includ intelli spinal cord stimul system
capit deploy mandatori repatri new tax bill might
chang mdt current capit deploy prioriti relat reinvest busi
share repurchas dividend within manag see
margin expans low-hang fruit seemingli pick margin expans
side drive increment margin improv critic success new
product launch achiev mdt oper margin goal mdt top-lin growth fall short
expect mid-single-digit rang longer term lever might compani pull
still deliv margin expans initi
portfolio reshap portfolio reshap activ like order add higher
growth higher margin busi also shed lower growth lower margin busi
non-strateg busi
capit need current burn rate quarterli perspect
reduc conserv cash cash hand exit long cash
posit fund daili oper compani conduct sever trial
financ option nvcn
reduc latest thought strategi reduc given compani commit
tiara fund develop thought partner reduc drive faster sale
expect see updat regulatori pathway reduc
growth trajectori manag expect ultim
manag view reduc market opportun
tiara mani patient implant date mani implant center
momentum seem build enrol last quarter current quarterli
enrol rate expect see updat dataset medic meet
tiara ii mani site enrol long take enrol patient
ce mark trial manag still expect ce mark submiss latest
thought trial trial design might
mitral competit landscap number differ valv develop
manag view competit landscap market support competitor
coapt data present tct transcathet cardiovascular therapi septemb
chang manag view mitral valv tiara
differenti transcathet mitral valv develop
transfemor transsept version tiara latest updat transfemor
transsept version tiara implant techniqu access rout
benefit product treatment sever mitral valv regurgit
market growth put take nvro market growth estim
competitor see market growth reconcil growth
project driver discrep pars one-tim item
sustain market growth outlook driver possibl
indic expans alter market growth profil
salesforc product sale rep hire effort go current attrit
trend sale rep see chang curv particularli given
search head sale still underway
market share manag expect gain share drive above-market growth
compani estim turnov salesforc still share gain
posit
competit landscap combat competit counter-detail
continu strengthen posit competit impact competit
launch bsx whisper mdt intelli market growth market share
pipelin expect updat diabet neuropathi still track
complet enrol much indic expand
indic mean term growth market broadli specif
 spine market spine market appear stabl improv rang
give management confid stabil us spine end-mkt rate factor give
management confid sustain above-market growth rate
margin expans mgmt long-term guidanc non-gaap oper margin beyond
revenue earn growth least sale growth still intact management still expect
least annual mgn expans beyond investor expect
cadenc non-linear
ceo focu area chri barri new ceo key strateg prioriti
beyond nuva new organiz structur announc help achiev
puls platform robot reason time-frame investor expect
launch robot solut compet exist spine robot much develop
runway compani disadvantag vs competit
robot arm offer complement puls platform
busi factor give management confid sustain growth
better busi beyond initi underway aid puerto
rico turnaround mkt offer greatest oppti acceler revenue growth
new ceo transit shacey petrov take ceo role key prioriti
next month area within compani warrant disproportion amount
focu right
transit pharmaci manag expect transit pharmaci channel
look like instal base expect go pharmaci channel end
give away potenti break barrier adopt patient
could actual driver better patient add annual revenu per patient
expect neutral free pdm uncertainti around time new patient start
pharmaci channel think impact revenu cadenc
quarter-to-quart think price drive acceler adopt
pharmaci channel
intern direct transit manag seen chang attrit new patient
add shift direct sale europ expect acceler new patient
add go forward countri repres compel opportun
pipelin latest updat horizon next step clinic trial
perspect horizon need show drive adopt certain reduct
reduc time hypo hyper horizon compar integr pump/cgm
system current market horizon adopt curv
next mileston project go-to-market strategi
gross margin profit gross margin ramp transit direct distribut
europ verg sustain profit compani invest new
manufactur facil peak gross margin potenti busi
increment driver oper leverag
 launch reimburs perspect latest updat market access
much access manag expect end mani physician
train sinc fda approv quickli physician ramp volum attend
train session earli adopt manag logist issu key
barrier adopt
cfo transit would current cfo elsey leav latest updat
potenti time new cfo criteria consid cfo search
european launch european launch progress reorder rate
patient notabl differ adopt and/or reorder pattern
recent launch eversens xl countri eversens avail
time manag estim market share new countri
come on-line
pipelin manag expect secur dose claim time key
new product launch includ eversens pediatr type
competit landscap manag view market dynam mdt
abt libr dxcm patient switch perspect patient ad
europ prior cgm user cgm reason believ
wont see trend eversens launch
 breast implant relaunch management think sale forc given go-
ahead fulli go offens target broader set prior user account
risk vesta inventori build result addit delay management fulli
confid beyond vesta reliabl satisfi sku physician order demand
textur breast implant issu expand management believ agn decis withdraw
textur implant tissu expand eu read market growth
could potenti tailwind/opportun breast implant suppli come back
on-line market risk categori and/or
 miradri busi factor management attribut slower-than-expect miradri
adopt give management confid us miradri placement continu
acceler us rep hire gone slowli origin expect
step compani take attract capit rep talent form
time expect around dtc campaign impact drive system placement
higher consum util miradri
miradri busi factor contribut overal strength intenational
busi sustain pace growth
invest prioriti margin street properli think increment invest
spend requir acceler revenu growth beyond dtc effort
sale forc hire management key invest prioriti
op leverag dd ep growth beyond base compani see right
reason think syk key end-mkt growth rate pois chang
ntm reason would end look like
org revenue growth low teen ep growth compani continu drive sale
out-performance rel long-rang plan -- -a -- -how much upsid management will
drop-through bottom line vs reinvest put take consid
vs top bottom line
mako kind impact manag expect anticip mako data
adopt technolog studi expect read time-frame realist
think total robot util rate continu climb strong level y/i
expect learn potenti expans opportun spine
analyst day management unveil plan robot shoulder said approv pathway would
like requir signific data would multi-year effort -- -what kind studi
associ timelin contempl
spine turnaround management minimize/ manag potenti dis-synergi relat
transact integr sale organ appreci certainli help build
scale still rel small player spine strategi build
supplement portfolio organ prod introduct tuck-in addit larger
deal still necessari go forward management see major product gap fill
portfolio compani latest view spinal cord stimul segment
eventu need offer space
neurovascular recent launch aspir system fill key product hole
enabl address ischem stroke treatment start aspir
progress stent retriev rescu -- -mgmt estim us/ww
target market earli feedback field initi launch
expect product begin meaning impact
futur area business/exist portfolio management think could benefit
inorgan vs organ invest cours assum asset avail right
price compani priorit small-mid-s target similar deal size ivti
entellu compani and/or consider
chang think larger transform deal much debt could
compani take fund deal
base biz ex neotract sustain growth process chang busi mix
shift and/or initi management point increas investor confid tfx
predictability/forecast relat core busi vs year
experienc uneven quarterli base biz growth order trend vari within year
neotract/urolift reason think urolift troubl achiev minimum revenue
mileston necessari trigger conting payout suspect high confid
target deal origin negoti shouldnt investor assum urolift
provid closer growth contribut vs management talk sinc
deal announc time-frame launch reimburs japan big
market oppti would upsid compani lrp kind revenue
impact expect launch urolift time-frame
repla percuv manta think revenue contribut potenti
product earliest potenti start contribut is/isnt factor
compani lt revenue growth guidanc assumpt relat product manta
least year mover advantag vs competit entrant us
competit arriv us give compet effect
time execut around op leverag target
pacing/cad annual basi respect margin improv
intend deliv lrp among driver op leverag -- -restructur
initi mix shift neotract leverag -- -around management most/least confid
present most/least execut risk management view
think
 intervent cardiolog busi area like focu inorgan build-
area equal like see complimentari interest
compani move addit vertic vs enhanc exist one tuck-in
management prioriti respect revenue growth accret vs willing deal ep dilut
consid tuck-in well potenti larger deal
key segment factor give management confid stabil high growth lower
upper extrem end-market larg and/or under-penetrated key
segment total ankl tar mi bunionectomi etc management still view compani
capabl grow top-lin mid-teen mid-teen long-term
key factor consid would allow compani mid-teen revenue grower
augment prostep much augment inject increment util effect vs
cannib exist augment legaci usag much bottleneck surgeon
train factor respect speed product launch like gain traction
contribut meaning increment sale expect prostep increment driver
ramp take longer ip barrier entri around
product like -- -what stop competitor develop similar type system
give management confid continu make share gain upper extrem
management anticip upper extrem growth trajectori impact new entrant
stemless shoulder categori exactech potenti road
penetr stemless market opportun to-dat much opportun still front
cartiva integr acquir cartiva aug excit addit
portfolio pma fda-approv cartilage-lik polym synthet cartilag implant
potenti dis-synergi management contempl cartiva revenue
guidanc sale forc integr progress plan integr
product sale forc
margin improvement/debt management see opportun get ebitda margin excess
current long-run object level top-lin growth structur chang op-
ex structur would necessari get ebitda margin rang
achiev long revenue growth trend dd territori requir mid-teen etc
although wmgi margin improv compani sg margin still stand one
highest med-tech compani -- -whi outlier taken
long gener op leverag how/when compani intend deal convert
refinanc like
organ reacceler back market rate long need happen
order return market growth rate still realist time-frame still
good estim zbh weight average end market growth improv visibl
whether management estim need revis rel bone cement headwind-
-- nov management expect bone cement fx togeth amount bottom line
headwind overcom
margin expans ep growth low-singl digit ep growth even growth
card given increment invest like necessari deal fx
headwind given capit remedi cost north campu take time
month work expect return msd-hsd ep growth rang
oper expens begin moder disproportion impact
suppli issu ebit begin revers realist time-frame
suppli remedi effort management still character suppli recoveri progress warrant
cautiou optim zbh previous commun timelin re-suppli still target
compani abl go offens management still view
warsaw north campu warn letter requir chang direct remedi
efforts/spend plan and/or compani discuss fda regard
need focu optim resourc alloc deal issu cite
robot rosa total knee applic enhanc compani abil regain
market share function offer vs competit robot system current
market would management open discount capit system exchang implant volum
commit launch timing/plan differ rosa applic across spine
knee brain alreadi commerci
 active/open management divestitur point turnaround
 area area prioriti inorgan front compani plan
dental busi consid core organ what management philosophi
regard trade revenue growth accret vs ep dilution/accret
total address market rais estim
manag assum total address market opportun maci ultim
expand address market opportun indic expans possibl exist
much expand
cartilag repair market hsgx come market chang manag
view growth opportun near-term long-term
ramp adopt maci mani physician target surgeon
train manag expect acceler train program quickli
physician ramp volum attend train session
convers rate manag seen notabl chang biopsi convers rate
would manag expect maci actual push convers rate higher wouldnt
biopsi convers rate chang time ultim move higher clinic data
necessari meaning convers surgeon
capit deploy cash exit recent rais shelf registr
potenti use cash posit come possibl
type asset would make sens busi criteria manag
consid evalu busi develop opportun current balanc
sheet size deal might abl compani deal
distract exist larg under-penetrated market opportun
